Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIA: Tazemetostat Combinations in Hematologic Malignancies
NCT05205252Phase 2Withdrawn
- Sponsor
- Epizyme, Inc.
- Start
- Dec 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tazemetostat in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma (MM), follicular lymphoma (FL), sponsored by Epizyme, Inc.. Planned start Dec 2021; status: withdrawn.
02
Drugs
tazemetostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)multiple myeloma (MM)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05205252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05205252.